The Biosimilars Generation website provides you with links to information about biosimilar regulations and policies in Canada.
Health Canada and other Canadian government regulators provide guidance on the safety, efficacy and quality of biologic (original-brand and biosimilar) medicines.
Canadian Agency for Drugs and Technologies in Health (CADTH)
Canadian Institute for Health Information
Patented Medicines Prices Review Board
Pan-Canadian Pharmaceutical Alliance
Biosimilars Reimbursement Access info
Public payers are adopting biosimilar policies that affect Canadians living with many disabling and life-threatening chronic diseases, such as inflammatory arthritis, certain types of cancer, diabetes, inflammatory bowel disease, Crohn’s disease and psoriasis.
Find more information about biosimilars and their listings on public drug plans.
For up-to-date information about biosimilars transition policy for each public formulary, please visit the websites below:
Ontario Health and Leslie Dan Faculty of Pharmacy, University of Toronto: Foundations of Originator and Biosimilar Biologics: for Patients and Caregivers
Ontario Ministry of Health. Executive Office Notice: Biosimilar Policy
Exceptional Access Program Reimbursement Criteria for Frequently Requested Drugs
Newfoundland and Labrador
Prince Edward Island
Non-insured Health Benefits (NIHB)